New hope for patients out of options: experimental drug enters first human trials
NCT ID NCT03547115
Summary
This early-stage study tested a new drug called voruciclib, both alone and combined with another drug (venetoclax), in adults with advanced blood cancers like leukemia and lymphoma. The main goal was to find safe dosage levels and see if the treatment showed any early signs of helping patients whose cancers had returned or stopped responding to standard therapies. The trial enrolled 84 participants and focused primarily on monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
New York University
New York, New York, 10016, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
Conditions
Explore the condition pages connected to this study.